表紙
市場調査レポート

非アルコール性脂肪性肝炎:パイプライン分析

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232818
出版日 ページ情報 英文 342 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
非アルコール性脂肪性肝炎:パイプライン分析 Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 342 Pages
概要

非アルコール性脂肪性肝炎(NASH)とは、肝臓に蓄積された脂肪肝により引き起こされる炎症です。肝臓の瘢痕化を発生・悪化させ、それがさらに硬変の原因ともなっています。主な症状には、倦怠感や原因不明の体重減少、全身の衰弱、腹部右側の腹痛などがあります。疾病素質として、肥満や2型糖尿病、高コレステロール、高中性脂肪(トリグリセリド)、メタボリック症候群などがあります。

当レポートでは、世界各国での非アルコール性脂肪性肝炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

非アルコール性脂肪性肝炎の概要

治療薬の開発

  • 非アルコール性脂肪性肝炎向けパイプライン製品:概要
  • 非アルコール性脂肪性肝炎向けパイプライン製品:比較分析

各企業で開発中の非アルコール性脂肪性肝炎治療薬

大学/研究機関で研究中の非アルコール性脂肪性肝炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

非アルコール性脂肪性肝炎治療薬:開発中の製品の一覧(企業別)

非アルコール性脂肪性肝炎治療薬:研究中の製品の一覧(大学/研究機関別)

非アルコール性脂肪性肝炎治療薬の開発に従事している企業

  • AlbireoPharma
  • Alnylam Pharmaceuticals, Inc.
  • Aquinox Pharmaceuticals Inc.
  • Arbutus Biopharma Corporation
  • Arisaph Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • BiOrion Technologies B.V.
  • Bird Rock Bio, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd.
  • Cardax Pharmaceuticals, Inc.
  • Cerenis Therapeutics Holding SA
  • Conatus Pharmaceuticals Inc.
  • Connexios Life Sciences Pvt. Ltd.
  • 第一三共
  • Dr. Falk Pharma GmbH
  • DURECT Corporation
  • Dynavax Technologies Corporation
  • Enanta Pharmaceuticals, Inc.
  • Exicure, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galectin Therapeutics, Inc.
  • Galmed Pharmaceuticals Ltd.
  • Genfit SA
  • GenKyoTex S.A.
  • Gilead Sciences, Inc.
  • Immuron Limited
  • Intercept Pharmaceuticals, Inc.
  • Inventiva SAS
  • Ionis Pharmaceuticals, Inc.
  • Jenrin Discovery, Inc.
  • キッセイ薬品工業
  • キョーリン製薬
  • Medivation, Inc.
  • Merck & Co., Inc.
  • Metabolic Solutions Development Company, LLC
  • Naia Limited
  • NGM Biopharmaceuticals, Inc.
  • Nimbus Therapeutics, LLC
  • 日本ケミファ
  • Nitto Denko Corporation
  • Novartis AG
  • NovaTarg Therapeutics, Inc
  • Novo Nordisk A/S
  • Pharmaxis Limited
  • Promethera Biosciences S.A.
  • ProMetic Life Sciences Inc.
  • Protalix BioTherapeutics, Inc.
  • Regulus Therapeutics Inc.
  • Shire Plc
  • Stelic Institute & Co., Inc.
  • TaiwanJ Pharmaceuticals Co., Ltd.
  • Therapix Biosciences Ltd
  • Tobira Therapeutics, Inc.
  • Vascular Biogenics Ltd.
  • Verlyx Pharma Inc.
  • Verva Pharmaceuticals Limited
  • Viking Therapeutics, Inc.
  • Virobay Inc.
  • Zafgen Inc.
  • Zydus Cadila Healthcare Limited

非アルコール性脂肪性肝炎:治療薬の評価

  • 単剤治療薬の場合
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (ロイシン + 塩酸メトホルミン + クエン酸シルデナフィル) 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • (ロイシン + PDE5 インヒビター)
  • A-4250
  • AM-0010
  • AQX-1125
  • Aramchol
  • ARI-3037MO
  • bertilimumab
  • BMS-986036
  • BMS-986171
  • BOT-191
  • CDX-085
  • cenicriviroc mesylate
  • CER-209
  • CF-102
  • CNX-014
  • CNX-023
  • CNX-024
  • CNX-025
  • DRX-065
  • DUR-928
  • DV-1179
  • EDP-305
  • elafibranor
  • emricasan
  • etanercept のバイオシミラー
  • GKT-831
  • GRMD-02
  • GS-9674
  • HepaStem
  • IMM-124E
  • IONIS-DGAT2Rx
  • IVA-337
  • JD-5037
  • JKB-119
  • JKB-121
  • linagliptin
  • liraglutide (組換型)
  • LJN-452
  • MAT-8800
  • MDV-4463
  • methazolamide
  • 循環器系/中枢神経系/消化器/免疫/代謝性疾患・感染症向け CD3阻害モノクローナル抗体
  • MSDC-0602
  • NC-101
  • NC-2400
  • ND-630
  • ND-654
  • ND-L02s0201
  • NDI-010976
  • NGM-282
  • norursodeoxycholic acid
  • NP-201
  • obeticholic acid
  • 非アルコール性脂肪性肝炎向けオリゴヌクレオチド
  • PBI-4050
  • pentamidine isethionate
  • Px-103
  • PXS-4728A
  • PXS-5033A
  • PZ-235
  • remogliflozin etabonate
  • RG-125
  • RG-6125
  • 循環器疾患・代謝障害・非アルコール性脂肪性肝炎向け RNAiオリゴヌクレオチド
  • RYI-018
  • saroglitazar
  • selonsertib
  • simtuzumab
  • 非アルコール性脂肪性肝炎向け小分子
  • 非アルコール性脂肪性肝・非アルコール性脂肪肝疾患向け小分子
  • 非アルコール性脂肪性肝炎向け SCD-1阻害剤
  • 脂肪肝疾患向け AMPK活性剤
  • 非アルコール性脂肪性肝炎向け MLK3阻害剤
  • solithromycin
  • SR-9238
  • STNM-09
  • TGFTX-3
  • tipelukast
  • TKM-HTG
  • TRX-318
  • VB-201
  • VBY-376
  • VK-0214
  • VK-2809
  • volixibat potassium
  • VVP-100-X
  • ZGN-839
  • ■非アルコール性脂肪性肝炎治療薬:パイプライン製品の最新動向

非アルコール性脂肪性肝炎治療薬:開発が休止状態の製品

非アルコール性脂肪性肝炎治療薬:開発が中止された製品

非アルコール性脂肪性肝炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8327IDB

Summary

Global Markets Direct's, 'Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016', provides an overview of the Non-Alcoholic Steatohepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis
  • The report reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Non-Alcoholic Steatohepatitis therapeutics and enlists all their major and minor projects
  • The report assesses Non-Alcoholic Steatohepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Non-Alcoholic Steatohepatitis Overview
  • Therapeutics Development
    • Pipeline Products for Non-Alcoholic Steatohepatitis - Overview
    • Pipeline Products for Non-Alcoholic Steatohepatitis - Comparative Analysis
  • Non-Alcoholic Steatohepatitis - Therapeutics under Development by Companies
  • Non-Alcoholic Steatohepatitis - Therapeutics under Investigation by Universities/Institutes
  • Non-Alcoholic Steatohepatitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Non-Alcoholic Steatohepatitis - Products under Development by Companies
  • Non-Alcoholic Steatohepatitis - Products under Investigation by Universities/Institutes
  • Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development
    • Akarna Therapeutics Ltd.
    • AlbireoPharma
    • Alnylam Pharmaceuticals, Inc.
    • Amunix Operating Inc.
    • Aquinox Pharmaceuticals Inc.
    • Arisaph Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • BiOrion Technologies B.V.
    • Bird Rock Bio, Inc.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Can-Fite BioPharma Ltd.
    • Cardax Pharmaceuticals, Inc.
    • Catabasis Pharmaceuticals, Inc.
    • Cerenis Therapeutics Holding SA
    • Conatus Pharmaceuticals Inc.
    • Connexios Life Sciences Pvt. Ltd.
    • Daiichi Sankyo Company, Limited
    • DURECT Corporation
    • Dynavax Technologies Corporation
    • Eli Lilly and Company
    • Enanta Pharmaceuticals, Inc.
    • Exicure, Inc.
    • Galectin Therapeutics, Inc.
    • Galmed Pharmaceuticals Ltd.
    • Genextra S.p.a.
    • Genfit SA
    • GenKyoTex S.A.
    • Gilead Sciences, Inc.
    • GRI Bio, Inc.
    • iCo Therapeutics Inc.
    • Immuron Limited
    • Inventiva
    • Ionis Pharmaceuticals, Inc.
    • Ixchel Pharma, LLC
    • Jenrin Discovery, Inc.
    • Kissei Pharmaceutical Co., Ltd.
    • Kyorin Pharmaceutical Co., Ltd.
    • Matinas BioPharma Holdings, Inc.
    • Merck & Co., Inc.
    • Mitochon Pharmaceuticals, Inc.
    • Naia Limited
    • NGM Biopharmaceuticals, Inc.
    • Nimbus Therapeutics, LLC
    • Nippon Chemiphar Co., Ltd.
    • Nitto Denko Corporation
    • Novartis AG
    • NovaTarg Therapeutics, Inc
    • Nuevolution AB
    • Pharmaxis Limited
    • Promethera Biosciences S.A.
    • ProMetic Life Sciences Inc.
    • Protalix BioTherapeutics, Inc.
    • Saje Pharma, LLC
    • Shire Plc
    • Stelic Institute & Co., Inc.
    • Sucampo Pharmaceuticals, Inc.
    • TaiwanJ Pharmaceuticals Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Therapix Biosciences Ltd
    • Tobira Therapeutics, Inc.
    • Vascular Biogenics Ltd.
    • Verlyx Pharma Inc.
    • Viking Therapeutics, Inc.
    • Virobay Inc.
    • Zafgen Inc.
    • Zydus Cadila Healthcare Limited
  • Non-Alcoholic Steatohepatitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile
    • (leucine + PDE5 Inhibitor) - Drug Profile
    • A-4250 - Drug Profile
    • AC-261066 - Drug Profile
    • AM-0010 - Drug Profile
    • AMX-342 - Drug Profile
    • Antisense Oligonucleotides for Non-Alcoholic Steatohepatitis - Drug Profile
    • AQX-1125 - Drug Profile
    • Aramchol - Drug Profile
    • ARI-3037MO - Drug Profile
    • AZD-4076 - Drug Profile
    • bertilimumab - Drug Profile
    • BMS-986036 - Drug Profile
    • BMS-986171 - Drug Profile
    • BOT-191 - Drug Profile
    • CAT-2000 Series - Drug Profile
    • CAT-2054 - Drug Profile
    • CDX-085 - Drug Profile
    • cenicriviroc mesylate - Drug Profile
    • CER-209 - Drug Profile
    • CF-102 - Drug Profile
    • CNX-014 - Drug Profile
    • CNX-023 - Drug Profile
    • CNX-024 - Drug Profile
    • CNX-025 - Drug Profile
    • DRX-065 - Drug Profile
    • DUR-928 - Drug Profile
    • DV-1179 - Drug Profile
    • EDP-305 - Drug Profile
    • elafibranor - Drug Profile
    • emricasan - Drug Profile
    • etanercept biosimilar - Drug Profile
    • evogliptin - Drug Profile
    • GKT-831 - Drug Profile
    • GRI-0621 - Drug Profile
    • GRMD-02 - Drug Profile
    • GS-9674 - Drug Profile
    • HepaStem - Drug Profile
    • IMM-124E - Drug Profile
    • IONIS-DGAT2Rx - Drug Profile
    • IVA-337 - Drug Profile
    • IXC-303 - Drug Profile
    • IXC-305 - Drug Profile
    • JD-5037 - Drug Profile
    • JKB-119 - Drug Profile
    • JKB-121 - Drug Profile
    • linagliptin - Drug Profile
    • LJN-452 - Drug Profile
    • MAT-8800 - Drug Profile
    • MGL-3196 - Drug Profile
    • MGL-3745 - Drug Profile
    • MP-301 - Drug Profile
    • MSDC-0602 - Drug Profile
    • MT-2002 - Drug Profile
    • NC-101 - Drug Profile
    • NC-2400 - Drug Profile
    • ND-630 - Drug Profile
    • ND-654 - Drug Profile
    • ND-L02s0201 - Drug Profile
    • NDI-010976 - Drug Profile
    • NGM-282 - Drug Profile
    • NGM-313 - Drug Profile
    • NGM-386 - Drug Profile
    • NGM-395 - Drug Profile
    • NP-201 Program - Drug Profile
    • obeticholic acid - Drug Profile
    • PBI-4050 - Drug Profile
    • pentamidine isethionate - Drug Profile
    • PXS-4728A - Drug Profile
    • PXS-5033A - Drug Profile
    • PZ-235 - Drug Profile
    • remogliflozin etabonate - Drug Profile
    • RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders - Drug Profile
    • RTU-1096 - Drug Profile
    • RYI-018 - Drug Profile
    • saroglitazar - Drug Profile
    • selonsertib - Drug Profile
    • selonsertib + simtuzumab - Drug Profile
    • simtuzumab - Drug Profile
    • Small Molecule for Non-Alcoholic Steatohepatitis - Drug Profile
    • Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile
    • Small Molecule to Agonize FXR for NASH and Liver Fibrosis - Drug Profile
    • Small Molecule to Inhibit DGAT-2 for Dyslipidemia and Non-Alcoholic Steatohepatitis - Drug Profile
    • Small Molecule to Inhibit SCD-1 for Non-alcoholic Steatohepatitis - Drug Profile
    • Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile
    • Small Molecules to Antagonize Integrin for Non-Alcoholic Steatohepatitis - Drug Profile
    • Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile
    • Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile
    • Small Molecules to Inhibit MLK3 for Non-Alcoholic Steatohepatitis - Drug Profile
    • Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis - Drug Profile
    • solithromycin - Drug Profile
    • SPL-891.1 - Drug Profile
    • SR-9238 - Drug Profile
    • STNM-09 - Drug Profile
    • TEV-45478 - Drug Profile
    • TGFTX-3 - Drug Profile
    • tipelukast - Drug Profile
    • TRX-318 - Drug Profile
    • VB-201 - Drug Profile
    • VB-703 - Drug Profile
    • VBY-376 - Drug Profile
    • VK-2809 - Drug Profile
    • volixibat potassium - Drug Profile
    • ZGN-839 - Drug Profile
  • Non-Alcoholic Steatohepatitis - Dormant Projects
  • Non-Alcoholic Steatohepatitis - Discontinued Products
  • Non-Alcoholic Steatohepatitis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2016
  • Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Akarna Therapeutics Ltd., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by AlbireoPharma, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Amunix Operating Inc. , H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Aquinox Pharmaceuticals Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by AstraZeneca Plc, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by BiOrion Technologies B.V., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Bird Rock Bio, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Can-Fite BioPharma Ltd., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Cerenis Therapeutics Holding SA, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by DURECT Corporation, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Dynavax Technologies Corporation, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Eli Lilly and Company, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Exicure, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Galectin Therapeutics, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Galmed Pharmaceuticals Ltd., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Genextra S.p.a., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Genfit SA, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by GenKyoTex S.A., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Gilead Sciences, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by GRI Bio, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by iCo Therapeutics Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Immuron Limited, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Inventiva, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Ixchel Pharma, LLC, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Jenrin Discovery, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Merck & Co., Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Naia Limited, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Nimbus Therapeutics, LLC, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Nitto Denko Corporation, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Novartis AG, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by NovaTarg Therapeutics, Inc, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Nuevolution AB, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Pharmaxis Limited, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Promethera Biosciences S.A., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Saje Pharma, LLC, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Shire Plc, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Stelic Institute & Co., Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Therapix Biosciences Ltd, H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Tobira Therapeutics, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Vascular Biogenics Ltd., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Verlyx Pharma Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Viking Therapeutics, Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Virobay Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Zafgen Inc., H2 2016
  • Non-Alcoholic Steatohepatitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Non-Alcoholic Steatohepatitis - Dormant Projects, H2 2016
  • Non-Alcoholic Steatohepatitis - Dormant Projects (Contd..1), H2 2016
  • Non-Alcoholic Steatohepatitis - Dormant Projects (Contd..2), H2 2016
  • Non-Alcoholic Steatohepatitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2016
  • Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top